SuperworthEvolus market cap EOLS
Share price times shares outstanding: what the whole company sells for, since 2018.
- Today, Oct 23, 2026
- $463M
- Highest close in our data
- $1.1B
- Sep 2024
Evolus is worth $463M at the close on Oct 23, 2026, at $7.01 a share.
That is up 5% over the last year and up 8% over five years.
Its highest close in our data was $1.1B in Sep 2024.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $463M | $260.9M | $614.3M | +4% |
| 2025 | $447.3M | $381.6M | $933.4M | −36% |
| 2024 | $702.2M | $597.2M | $1.1B | +17% |
| 2023 | $601.8M | $407M | $621.5M | +42% |
| 2022 | $422.4M | $296.2M | $762.8M | +17% |
| 2021 | $361.8M | $143.1M | $722.5M | +219% |
| 2020 | $113.4M | $102.3M | $317.3M | −65% |
| 2019 | $326.1M | $326.1M | $773.5M | +0% |
| 2018 | $324.6M | $288.3M | $778.7M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Evolus' size, closest first, today.
| Company | Market cap |
|---|---|
| EOLSEvolus | $463M |
| ARVNArvinas | $477.3M |
| PBYIPuma Biotechnology | $568.9M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| ZVRAZevra Therapeutics | $582.6M |
| CRMDCorMedix | $611.9M |
| COLLCollegium Pharmaceutical | $747.5M |
| ABUSArbutus Biopharma | $831M |
| NATRNatures Sunshine Products | $213.8M |
| AMPHAmphastar Pharmaceuticals | $1.1B |
| OMEROmeros | $1.2B |
| Peer median | $597.2M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Evolus
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.